Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market

BACKGROUND: Cetuximab is a monoclonal antibody which acts against the epidermal growth-factor receptor. Randomized controlled trials show that the addition of cetuximab to folinic acid, 5-flourouracil, irinotecan (FOLFIRI), folinic acid, 5-flourouracil, oxaliplatin (FOLFOX) and capecitabin + oxalipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Davari, Majid, Ashrafi, Farzaneh, Maracy, Mohammadreza, Aslani, Abolfazl, Tabatabaei, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521302/
https://www.ncbi.nlm.nih.gov/pubmed/26288707
http://dx.doi.org/10.4103/2008-7802.161068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521302/
https://www.ncbi.nlm.nih.gov/pubmed/26288707
http://dx.doi.org/10.4103/2008-7802.161068

Ejemplares similares